COPENHAGEN, Denmark, Feb. 10, 2010 (GLOBE NEWSWIRE) -- Today, at the 5th Annual CHDI Conference on Huntington’s disease, held 8 to 11 February in Palm Springs, California, NeuroSearch (NEUR.CO) presented the results from the MermaiHD study, a Phase III study with Huntexil(r) (pridopidine) for the treatment of Huntington’s disease. Top-line results from the study were announced on 3 February 2010 (Announcement no. 01-10),
